Dry Eye Syndrome Treatment Market by treatment type (Lubricant Eye Drops, Anti-inflammatory Drugs, Autologous Serum Eye Drops, Nutrition supplements), disease type (Evaporative dry eye syndrome, Aqueous dry eye syndrome), distribution channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Others) and Geography  

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Dry Eye Syndrome Treatment Market Size was valued at USD 5.87 billion in 2021 and expected to reach a value of USD  10.81 billion by 2028, growing at a CAGR of 9.11% during the forecast period 2022-2028. Dry eye syndrome (keratoconjunctivitis sicca), is an ocular disease caused by the lack of tear fluid to lubricate the eyes, which leads to problems in vision, tear film instability, and discomfort causes potential damage to the ocular surface. Dry eye syndrome can also cause due to other ocular surface diseases such as ocular allergy and meibomian gland dysfunction. The ocular surface contains 7 components including lacrimal and accessory lacrimal apparatus. Any abnormalities in one of the ocular surface components may cause the dry eye syndrome. Dry eye syndrome is classified into two types namely, evaporative dry eye and pure aqueous deficiency dry eye. The common symptoms associated with dry eye syndrome include ocular irritation, hyperaemia, mucoid discharge, blurred vision, excessive tearing, ocular dryness, photophobia, and grittiness. Dry eye syndrome is measured by a thin strip of filter paper placed at the edge of the eye, called a Schirmer test to measure the amount of tears present in the eye. Global dry eye syndrome treatment market is in the developing stage owing to increase in the research and development activities by the competitors in the dry eye syndrome treatment market. The patents of various dry eye syndrome treatment drugs are in expiry stage, so various pharmaceutical companies are actively involved in the R&D of new drugs. Some of the key strategies followed by various pharmaceutical companies to increase revenue share in global dry eye syndrome treatment market including acquisitions & mergers, collaborations, and launching of new products. For instance, in July 2013, Novaliq GmbH won European approval for its lubricating, drug-delivering eye drop NovaTears, designed for over-the-counter treatment of dry eye syndrome. Similarly, in June 2015,  Allergan plc, a pharmaceutical company acquired Oculeve Inc, a medical device company that focuses on new technologies for dry eye disease to improve market position in the dry eye syndrome treatment market. In addition, in January 2017, Novaliq announced the positive top-line results of phase 2 clinical trial evaluating CyclASol in adults with moderate to severe dry eye disease.

Global Dry Eye Syndrome Treatment Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market

North America
Dry Eye Syndrome Treatment Market Dynamics

The global dry eye syndrome treatment market is expected to grow at a significant CAGR due to rise in the geriatric population (tear glands weaken due to aging and can’t produce sufficient tear fluid to maintain a lubricating film over the eyes) and increase in the prevalence of dry eye syndrome. The increase in the prevalence of diabetes, vitamin A deficiency, lupus, thyroid disorders, and rheumatoid arthritis might fuel the dry eye syndrome treatment market. Moreover, increasing awareness among the population about diagnosis and treatment of dry eye syndrome, steady government support for medical research has allowed researchers to treat this condition more precisely and comprehensively, external stimuli such as laser eye surgery, and computer screen overuse are key factors also boosting the dry eye syndrome treatment market over the forecast period. However, expiration of blockbuster drug patents, the popularity of self-medication by patients is the major restraints for the dry eye syndrome treatment market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Dry Eye Syndrome Treatment Market Segmentation

  • Lubricant Eye Drops
    • Preservative-Free Drops
    • Oily Tear Eye Drops
    • Eye Ointments
  • Anti-inflammatory Drugs
    • Corticosteroids
    • Tetracyclines Oral
  • Autologous Serum Eye Drops
  • Nutrition supplements
  • Evaporative dry eye syndrome
  • Aqueous dry eye syndrome
Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others

Frequently Asked Questions

The dry eye syndrome treatment market is projected to expand at a CAGR of 9.11% during the forecast period

Nicox (France), Allergan (U.S.), Auven Therapeutics (U.S.), Novartis AG (Switzerland), AFT Pharmaceuticals (New Zealand)

North America is the fastest-growing region for dry eye syndrome treatment market

[urltag url='request-table-of-content']

  • Novartis AG (Switzerland)
  • Nicox (France)
  • Allergan (U.S.)
  • Santen Pharmaceutical Co., Ltd. (Japan)
  • Otsuka Holdings Co., Ltd. (Japan)
  • Auven Therapeutics (U.S.)
  • AFT Pharmaceuticals (New Zealand)
  • I-Med Pharma, Inc. (Canada)
  • Sun Pharmaceuticals Industries Ltd. (India)
  • Mimetogen Pharmaceuticals (U.S.)
  • Novaliq GMBH (Germany)